Table 2

Clinical details of screen detected lung cancers

ID	Sex	Age	PS	MRC	TNM	Final stage	Pathological type	Histology subtype (resected adenocarcinomas)	Treatment
1	M	57	1	1	cT1a N0 M0	IA	Adenocarcinoma	–	Radiotherapy^(R)
2	F	61	2	3	pT1a N0	IA	Adenocarcinoma	Undetermined	Surgery
3	F	69	0	1	pT1a N0	IA	Squamous	–	Surgery
4	F	65	0	1	pT1a N0	IA	Adenocarcinoma	Acinar	Surgery
5	F	74	1	1	pT1a N0	IA	Adenocarcinoma	Acinar	Surgery
6	F	70	0	1	pT1b N0	IA	Adenocarcinoma	Lepidic 40%, papillary 35%, acinar 20%, solid 5%	Surgery
7^A	F	60	3	4	pT1a Nx	IA	Adenocarcinoma	Acinar	Surgery
8^A					pT1a Nx	IA	Adenocarcinoma	Papillary
9^A					pT1a Nx	IA	Adenocarcinoma	Acinar
10	F	74	2	4	cT1b N0 M0	IA	Clinical	–	Surgery—declined
11	M	69	0	1	pT1a N0	IA	Adenocarcinoma	Papillary	Surgery
12	M	66	0	1	pT1a N0	IA	Squamous	–	Surgery
13	F	65	1	1	pT1a N0	IA	Adenocarcinoma	Lepidic 90%, acinar 10%*	Surgery
14^B	F	74	1	1	pT1a N0	IA	Adenosquamous	Acinar	Surgery
15^B	F	74	1	1	pT1a N0	IA	Squamous	–	Surgery
16	F	72	2	1	pT1b N0	IA	Typical carcinoid	–	Surgery
17	M	73	0	1	pT1a N0	IA	Adenocarcinoma	Acinar	Surgery
18	M	64	1	1	cT1a N0 M0	IA	Clinical	–	SABR
19	F	65	1	2	pT1a N0	IA	Adenocarcinoma	Acinar 80%, lepidic 20%	Surgery
20	F	73	0	1	cT1a N0 M0	IA	Clinical	–	Surgery—declined
21	F	72	0	2	pT1a N0	IA	Squamous	–	Surgery
22^C	F	73	1	1	pT1aN0	IA	Adenocarcinoma	Acinar 70%, lepidic 30%	Surgery
23^C	F	73	1	1	pT2aN0	IB	Squamous	–	Surgery
24	M	70	0	1	pT2a N0	IB	Adenocarcinoma	Mixed acinar (>10%), lepidic, papillary	Surgery
25	F	71	0	1	pT2a N0	IB	Squamous	–	Surgery
26	M	67	1	3	pT2a N0	IB	Adenocarcinoma	Lepidic 55%, papillary 40%, acinar 5%	Surgery
27	F	64	1	4	pT2a N0	IB	Adenocarcinoma	Solid 90%, acinar 10%	Surgery
28	F	67	1	3	pT2a N0	IB	Adenocarcinoma	Acinar 95%, lepidic 5%	Surgery
29	F	62	3	4	cT2 N0 M0	IB	Squamous	–	SABR
30	F	60	0	1	cT1a N1 M0	IIA	Small	–	Chemoradiotherapy^(C)
31	M	68	1	2	pT1a N1	IIA	Adenosquamous	Solid	Surgery/chemotherapy^(A)
32	M	63	0	1	cT1 N1 M0	IIA	Squamous	–	Radiotherapy^(R)
33	M	72	1	2	pT2b N0	IIA	Adenocarcinoma	Acinar	Surgery
34	M	69	3	5	cT1a N1 M0	IIA	Small	–	Chemotherapy
35	F	70	1	2	pT3 N0	IIB	Adenocarcinoma	Acinar 50%, lepidic 40%, papillary 10%	Surgery
36	M	73	0	1	cT3 N0 M0	IIB	Squamous	–	Radiotherapy^(R)
37	M	57	3	5	cT3 N0 M0	IIB	Clinical	–	Radiotherapy^(R)
38	F	61	0	1	pT2a N2	IIIA	Squamous	–	Surgery/chemotherapy^(A)
39	M	65	0	2	pT2a N2	IIIA	Adenocarcinoma	Acinar 60%, lepidic 30%, solid 5%, papillary 5%	Surgery/chemotherapy^(A)
40	M	74	0	1	cT4 N2 M0	IIIA	Squamous	–	Chemoradiotherapy^(S)
41	M	73	0	1	pT4 N2	IIIB	Squamous	–	Surgery/chemotherapy^(A)
42	F	65	2	3	cT4 N0 M1a	IV	Adenocarcinoma	–	Chemotherapy
43	F	66	1	1	cT4 N2 M1b	IV	Adenocarcinoma	–	Radiotherapy^(P)
44	M	63	0	1	cT4 N2 M1b	IV	Squamous	–	Chemotherapy—declined
45	F	71	0	1	cT2 N2 M1b	IV	Adenocarcinoma	–	Chemoradiotherapy^(S)
46	M	71	2	4	cT4 N1 M1b	IV	Adenocarcinoma	–	Chemotherapy

(R) Radical treatment, ^(C)concurrent treatment, ^(S)sequential treatment, ^(P)palliative treatment, ^(A)adjuvant chemotherapy. ^A,B,C, cancers in the same patient.
TNM staging using V.7.
*Case with a rapid development of a solid component over 3 months.
MRC, Medical Research Council; PS, performance status; SABR, stereotactic ablative radiotherapy; TNM, tumour, node and metastasis.